BRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product Revenue

Reuters

04-30

BRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product Revenue

April 30 (Reuters) - Surmodics Inc SRDX.O:

SURMODICS EXPECTS FY25 FINANCIAL PERFORMANCE TO REMAIN IMPACTED BY LOWER SURVEIL DCB LICENSE FEE, PRODUCT REVENUE
SURMODICS EXPECTS FY25 FINANCIAL GUIDANCE DOES NOT REFLECT POSSIBLE TARIFF IMPACTS
SURMODICS TARIFF EXPOSURE RELATED TO SUPPLY CHAIN REPRESENTS MODEST PERCENTAGE OF TOTAL PRODUCT SALES
SURMODICS TARIFF EXPOSURE FROM CUSTOMER MEDICAL DEVICE AND TEST KIT SALES IS DIFFICULT TO QUANTIFY

Further company coverage: SRDX.O

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2531903305"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531903305\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2531903305?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-30 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531903305","market":"nz","top_or_hot":-1,"title":"BRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product Revenue","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product Revenue</title></head><body><p><span>April 30 (Reuters)</span><span> - </span>Surmodics Inc <span>SRDX.O</span>:</p><ul><li><p>SURMODICS EXPECTS FY25 FINANCIAL PERFORMANCE TO REMAIN IMPACTED BY LOWER SURVEIL DCB LICENSE FEE, PRODUCT REVENUE</p></li><li><p>SURMODICS EXPECTS FY25 FINANCIAL GUIDANCE DOES NOT REFLECT POSSIBLE TARIFF IMPACTS</p></li><li><p>SURMODICS TARIFF EXPOSURE RELATED TO SUPPLY CHAIN REPRESENTS MODEST PERCENTAGE OF TOTAL PRODUCT SALES</p></li><li><p>SURMODICS TARIFF EXPOSURE FROM CUSTOMER MEDICAL DEVICE AND TEST KIT SALES IS DIFFICULT TO QUANTIFY</p></li></ul><p>Further company coverage: <span>SRDX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-30 19:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product Revenue</title></head><body><p><span>April 30 (Reuters)</span><span> - </span>Surmodics Inc <span>SRDX.O</span>:</p><ul><li><p>SURMODICS EXPECTS FY25 FINANCIAL PERFORMANCE TO REMAIN IMPACTED BY LOWER SURVEIL DCB LICENSE FEE, PRODUCT REVENUE</p></li><li><p>SURMODICS EXPECTS FY25 FINANCIAL GUIDANCE DOES NOT REFLECT POSSIBLE TARIFF IMPACTS</p></li><li><p>SURMODICS TARIFF EXPOSURE RELATED TO SUPPLY CHAIN REPRESENTS MODEST PERCENTAGE OF TOTAL PRODUCT SALES</p></li><li><p>SURMODICS TARIFF EXPOSURE FROM CUSTOMER MEDICAL DEVICE AND TEST KIT SALES IS DIFFICULT TO QUANTIFY</p></li></ul><p>Further company coverage: <span>SRDX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRDX","symbol_name":"SurModics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R81YC:1","article_id":"2531903305","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531903305","pubTimestamp":1746012381,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product RevenueApril 30  - Surmodics Inc SRDX.O:SURMODICS EXPECTS FY25 FINANCIAL PERFORMANCE TO REMAIN IMPACTED BY LOWER SURVEIL DCB LICENSE FEE, PRODUCT REVENUESURMODICS EXPECTS FY25 FINANCIAL GUIDANCE DOES NOT REFLECT POSSIBLE TARIFF IMPACTSSURMODICS TARIFF EXPOSURE RELATED TO SUPPLY CHAIN REPRESENTS MODEST PERCENTAGE OF TOTAL PRODUCT SALESSURMODICS TARIFF EXPOSURE FROM CUSTOMER MEDICAL DEVICE AND TEST KIT SALES IS DIFFICULT TO QUANTIFYFurther company coverage: SRDX.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SRDX":"SurModics"},"translate_title":"简介-Surmodics预计2025财年财务业绩仍将受到Surveil DCB许可费和产品收入下降的影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRDX":0.9},"content_text":"BRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product RevenueApril 30 (Reuters) - Surmodics Inc SRDX.O:SURMODICS EXPECTS FY25 FINANCIAL PERFORMANCE TO REMAIN IMPACTED BY LOWER SURVEIL DCB LICENSE FEE, PRODUCT REVENUESURMODICS EXPECTS FY25 FINANCIAL GUIDANCE DOES NOT REFLECT POSSIBLE TARIFF IMPACTSSURMODICS TARIFF EXPOSURE RELATED TO SUPPLY CHAIN REPRESENTS MODEST PERCENTAGE OF TOTAL PRODUCT SALESSURMODICS TARIFF EXPOSURE FROM CUSTOMER MEDICAL DEVICE AND TEST KIT SALES IS DIFFICULT TO QUANTIFYFurther company coverage: SRDX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}